ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Associations between Opium Route of Use and Exposure to Polycyclic Aromatic Hydrocarbons as Potential Carcinogenicity Mechanism.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Opioid biomarkers in urine as reliable and valid correlates of opium use characteristics: A 10-year longitudinal assessment.Drug and alcohol dependence reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundOpium consumption is carcinogenic, but the impact of the route of use (smoking vs. ingestion) on exposure to potential proposed carcinogens is understudied.
methodsAs a nested study within the Golestan Cohort Study, we gathered comprehensive histories of teriak (raw opium), shireh (refined opium sap), and tobacco use by validated questionnaires and selected 100 long-term opium users (50 exclusively ingesting and 50 exclusively smoking), 15 cigarette smokers, and a reference sample using neither. We analyzed spot urine samples for seven hydroxy polycyclic aromatic hydrocarbons (PAH) and cotinine. PAH biomarker concentrations were creatinine-corrected to account for urinary dilution and adjusted for demographic factors and opium use patterns using multivariable linear regression models to evaluate associations between the route of opium use and PAH biomarker concentrations.
resultsAfter excluding opium users who reported no tobacco use but had discordant cotinine concentrations, PAH biomarker concentrations were significantly higher in opium users than the reference sample. Smoking opium was associated with substantially elevated PAH biomarker concentrations compared with ingestion, particularly for Σ2,3-Hydroxyphenanthrene (five-fold increase) and 3-Hydroxyfluorene (4.5-fold increase). For Σ2,3-Hydroxyphenanthrene, concentrations exceeded those of cigarette smokers. No difference was observed between teriak and shireh use. Only among opium smokers, PAH biomarker concentrations decreased by time since last use but remained consistently higher than the reference sample.
conclusionsOpium consumption, regardless of type and route, exposes individuals to PAHs, with greater concentrations of select PAH biomarkers observed for smoking compared with ingestion. IMPACT: Considering the route of opium use in exposure and cancer risk assessments is crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.